Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Good morning, fellow Fools! It's time to check in on the movers and shakers in health care today.
Will Ariad continue to rally?
Ariad Pharmaceuticals (NASDAQ: ARIA ) looks to continue its rally today following the announcement last Friday that the U.S. Food and Drug Administration, or FDA, approved a revised Prescribing Information and a Risk Evaluation and Mitigation Strategy for the company's leukemia drug Iclusig. Per the revised label, Iclusig can now only be prescribed to patients with chronic myeloid leukemia who have failed to benefit from or are ineligible to take other alternative therapies, including Novartis AG's (NYSE: NVS ) Gleevec. Gleevec is currently a first-line treatment, whereas Iclusig is now a treatment of last resort in many ways.
What's my take? It's important to understand that Ariad shares have now rebounded more than 200% since imploding upon the FDA placing a partial clinical hold on Iclusig last October. Even more importantly, you should keep in mind that Iclusig is not a game-changer for Ariad. Despite being the company's only commercially available drug, Iclusig raked in less than $17 million in the third quarter, giving the company a $66 million net loss for the quarter. Given that Ariad's market cap is now a staggering $1.3 billion following this rally, I think Foolish investors would best be served by taking a pass on this one.
Supernus may pull back today
Supernus Pharmaceuticals (NASDAQ: SUPN ) looks like it will pull back today after soaring more than 13% last Tuesday. The stock is now up close to 20% over the last few sessions alone.
Supernus's rally was sparked by the FDA approving United Therapeutic's (NASDAQ: UTHR ) pulmonary arterial hypertension drug Orenitram. Orenitram was co-developed by Supernus, and the company will receive milestone and single-digit royalty payments as a result. Per the agreement, Supernus could receive a $2 million milestone payment based on the approval.
What's my view? I think this pullback is healthy. The licensing deal doesn't appear to be a game-changer for Supernus, unless Orenitram sales are out of sight. Overall, this approval is a much bigger deal for United Therapeutics.
Top Stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.